



Hang Seng Indexes Company Announces World's First Warrant Licensing for Hang Seng Biotech Index

Strengthens Hong Kong-Malaysia capital market connectivity

(Hong Kong, 9 September 2026) – Hang Seng Indexes Company has announced the world's first warrant licensing of the Hang Seng Biotech Index to Kenanga Investment Bank Berhad in Malaysia. This launch marks an important milestone in expanding Hang Seng Indexes Company's overseas index licensing activities and product offering.

This cross-market initiative is among the 30+ commercial outcome showcases at the 11th Belt and Road Summit, co-organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council. It underscores growing market demand for index-linked products across Belt and Road markets and strengthens capital market connectivity between Hong Kong and Malaysia.

The Hang Seng Biotech Index tracks the 30 largest biotechnology companies listed in Hong Kong and is eligible for trading via Southbound Stock Connect. The index has become a key benchmark reflecting the sector's innovation and development.

The Hang Seng Biotech Index rose 98.5% over the past two years as of 31 August 2026, underscoring strong recent investors' interest in biotech. With the launch of futures linked to the Hang Seng Biotech Index last year, the product ecosystem has been further broadened. On 20 August 2026, Hang Seng Biotech Index Futures recorded a new daily volume high of 1,414 contracts, reflecting rising demand for biotech exposure.

Nicholas Ho, Commissioner for Belt and Road of the HKSAR Government, said: "I am pleased to witness the collaborations reached today. Hong Kong, as a 'super connector', 'super value-adder', and resource orchestration hub for the Belt and Road, links enterprises with international capital and helps them expand into Belt and Road markets. By pioneering more sustainable and inclusive financial solutions, we aim to accelerate high-quality co-operation, foster deeper integration, shared prosperity, and a more resilient future for all participating economies."

Muzambli Markam, Consul General of Malaysia in Hong Kong SAR and Macao SAR, said: "We are delighted to witness this milestone collaboration between Kenanga Investment Bank Berhad and Hang Seng Indexes Company. As Malaysia advances its New Industrial Master Plan 2030 and strengthens its high-value healthcare and biotechnology ecosystem, this partnership directly aligns with our national aspiration to expand innovative, cross-border financial products. By connecting Malaysian investors to Hong Kong's world-class indexes and capital markets, we are driving deeper economic integration and highlighting Malaysia's role as a vibrant investment destination in the region."



Hang Seng Indexes Company Announces First Warrant Licensing for Hang Seng Biotech Index / 2

Gilbert Lee, Executive Chairman of Hang Seng Indexes Company, said, “Biotech is a strategic pillar for China's 15th Five-Year Plan and a key focus of Hong Kong’s I&T strategy, and we are proud to support the sector’s development through our index solutions. The launch of the world’s first warrant linked to the Hang Seng Biotech Index provides global investors with a broader range of index-linked tools. It also advances our ambition to develop the Hang Seng Biotech Index into another flagship benchmark¹. By extending our indexes into overseas markets, we are strengthening connectivity between Hong Kong and Malaysia, and facilitating cross-markets capital flows across Belt and Road markets. We will continue to deepen our overseas partnerships, expand the international reach of our indexes and reinforce Hong Kong's role as a super connector.”

- End -

¹ Flagship benchmarks are Hang Seng Indexes Company’s most widely tracked and best-recognised indexes with a comprehensive product ecosystem, substantial market share in index-linked products, and strong local media presence. This currently includes the Hang Seng Index, the Hang Seng China Enterprises Index, the Hang Seng TECH Index.



Hang Seng Indexes Company Announces First Warrant Licensing for Hang Seng Biotech Index / 3

Photo Caption

(From left to right) Nancy Cheng, Executive Director and Head of Operations of Hang Seng Indexes Company; Linda Luk, Executive Director and Product Strategist (ETF) of Hang Seng Indexes Company; Gilbert Lee, Executive Chairman of Hang Seng Indexes Company; Nicholas Ho, Commissioner for Belt and Road of the HKSAR Government; Muzambli Markam, Consul General of Malaysia in Hong Kong SAR and Macao SAR; Philip Lim, Head of Equity Markets, Group Head of Equity Derivatives of Kenanga Investment Bank Berhad, Kenneth Teoh, Deputy Head of Equity Derivatives, Head of Equity Derivatives Trading of Kenanga Investment Bank Berhad, and Isabelle Zhen, Head of Group Equity Marketing of Kenanga Investment Bank Berhad, celebrate the successful launch of the warrant linked to the Hang Seng Biotech Index at the 11th Belt and Road Summit.



About Hang Seng Indexes Company

Hang Seng Indexes Company manages and compiles the Hang Seng Family of Indexes, which cover stocks listed in Hong Kong and Chinese Mainland. Our index series includes the Hang Seng Index, the Hang Seng China Enterprises Index and the Hang Seng TECH Index, as well as Stock Connect, Greater Bay Area, Sustainability and sector-related indexes. As at the end of June 2026, assets under management in products passively tracking indexes in the Hang Seng Family of Indexes had reached a total of about USD106.6 billion. Hang Seng Indexes Company is a wholly owned subsidiary of Hang Seng Bank. For further information on the Hang Seng Family of Indexes, please visit www.hsi.com.hk.